Evaluation of a new Etest vancomycin-teicoplanin strip for detection of glycopeptide-intermediate Staphylococcus aureus (GISA), in particular, heterogeneous GISA.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: American Society for Microbiology Country of Publication: United States NLM ID: 7505564 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1098-660X (Electronic) Linking ISSN: 00951137 NLM ISO Abbreviation: J Clin Microbiol Subsets: MEDLINE
    • Publication Information:
      Original Publication: Washington, American Society for Microbiology.
    • Subject Terms:
      Anti-Bacterial Agents/*pharmacology ; Microbial Sensitivity Tests/*methods ; Staphylococcus aureus/*drug effects ; Teicoplanin/*pharmacology ; Vancomycin/*pharmacology; Drug Resistance, Bacterial ; Reagent Strips ; Sensitivity and Specificity ; Vancomycin Resistance
    • Abstract:
      Glycopeptide-intermediate Staphylococcus aureus (GISA) and, in particular, heterogeneous GISA (hGISA) are difficult to detect by standard MIC methods, and thus, an accurate detection method for clinical practice and surveillances is needed. Two prototype Etest strips designed for hGISA/GISA resistance detection (GRD) were evaluated using a worldwide collection of hGISA/GISA strains covering the five major clonal lineages. A total of 150 strains comprising 15 GISA and 60 hGISA strains (defined by population analysis profiles-area under the curve [PAP-AUC]), 70 glycopeptide-susceptible S. aureus (GSSA) strains, and 5 S. aureus ATCC reference strains were tested. For standardized Etest vancomycin (VA) MIC testing, the modified Etest macromethod with VA and teicoplanin (TP) strips tested with a heavier inoculum using brain heart infusion agar (BHI) and two glycopeptide screening agar plates (6 microg/ml VA/BHI and 5 microg/ml Mueller-Hinton agar [MHA]) were tested in parallel with the two new Etest GRD strips: a VA 32 (0.5-microg/ml)-TP 32 (0.5-microg/ml) double-sided gradient (E-VA/TP) with one prototype overlaid with a nutrient (E-VA/TP+S) to enhance the growth of hGISA. The Etest GRD strips were tested with a standard 0.5-McFarland standard inoculum using MHA and MHA plus 5% blood (MHB) and were read at 18 to 24 and 48 h. The interpretive MIC cutoffs used for the new Etest GRD strips at 24 and 48 h were as follows: for GISA, TP or VA, >or=8, and a standard VA MIC of >or=6; for hGISA, TP or VA, >or=8, and a standard VA MIC of
    • References:
      Clin Infect Dis. 2001 Jan;32(1):108-15. (PMID: 11118389)
      J Clin Microbiol. 2001 Jul;39(7):2439-44. (PMID: 11427551)
      J Clin Microbiol. 2001 Jan;39(1):241-50. (PMID: 11136778)
      Clin Infect Dis. 2004 Nov 15;39(10):1544; author reply 1544-5. (PMID: 15546096)
      Clin Infect Dis. 2004 Aug 15;39(4):539-45. (PMID: 15356818)
      Clin Infect Dis. 2003 Feb 15;36(4):429-39. (PMID: 12567300)
      Trends Microbiol. 2001 Oct;9(10):486-93. (PMID: 11597450)
      J Antimicrob Chemother. 2000 Jan;45(1):130-2. (PMID: 10629026)
      J Antimicrob Chemother. 2001 Apr;47(4):399-403. (PMID: 11266410)
      Clin Microbiol Infect. 2006 Mar;12 Suppl 1:16-23. (PMID: 16445720)
      Antimicrob Agents Chemother. 2005 Nov;49(11):4816; author reply 4816-7. (PMID: 16251343)
      Annu Rev Microbiol. 2002;56:657-75. (PMID: 12142482)
      Eur J Clin Microbiol Infect Dis. 2005 Feb;24(2):100-8. (PMID: 15682283)
      J Antimicrob Chemother. 1997 Jul;40(1):135-6. (PMID: 9249217)
      Biochim Biophys Acta. 2005 Nov 30;1726(3):326-7. (PMID: 16213099)
      Lancet. 1998 Feb 21;351(9102):602. (PMID: 9492814)
      Antimicrob Agents Chemother. 2005 Sep;49(9):3982-3. (PMID: 16127089)
      MMWR Morb Mortal Wkly Rep. 2004 Apr 23;53(15):322-3. (PMID: 15103297)
      Clin Infect Dis. 2004 Feb 1;38(3):448-51. (PMID: 14727222)
      Emerg Infect Dis. 2001 Mar-Apr;7(2):327-32. (PMID: 11294734)
      Curr Opin Infect Dis. 2005 Aug;18(4):300-5. (PMID: 15985825)
      J Antimicrob Chemother. 2005 Nov;56(5):944-7. (PMID: 16157619)
      MMWR Morb Mortal Wkly Rep. 2002 Oct 11;51(40):902. (PMID: 12418544)
      Emerg Infect Dis. 2004 May;10(5):855-7. (PMID: 15200819)
      Drugs. 1993 Mar;45(3):353-66. (PMID: 7682906)
      J Hosp Infect. 1999 Dec;43 Suppl:S3-7. (PMID: 10658753)
      Int J Med Microbiol. 2002 Jun;292(1):27-35. (PMID: 12139425)
      Curr Drug Targets Infect Disord. 2004 Dec;4(4):273-94. (PMID: 15578969)
      Lancet Infect Dis. 2001 Oct;1(3):147-55. (PMID: 11871491)
      J Clin Microbiol. 1998 Apr;36(4):1020-7. (PMID: 9542929)
      Intern Med J. 2005 Dec;35 Suppl 2:S136-40. (PMID: 16271057)
    • Accession Number:
      0 (Anti-Bacterial Agents)
      0 (Reagent Strips)
      61036-62-2 (Teicoplanin)
      6Q205EH1VU (Vancomycin)
    • Publication Date:
      Date Created: 20080704 Date Completed: 20090924 Latest Revision: 20211020
    • Publication Date:
      20231215
    • Accession Number:
      PMC2546754
    • Accession Number:
      10.1128/JCM.00265-08
    • Accession Number:
      18596146